Andrew S. Fein Analyst Performance

Andrew S. Fein is a stock analyst at HC Wainwright in the medical sector, covering 13 publicly traded companies. Over the past year, Andrew S. Fein has issued 14 stock ratings, including buy and hold recommendations. While full access to Andrew S. Fein's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrew S. Fein's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

14 Last 0 Years

Buy Recommendations

92.86% 13 Buy Ratings

Companies Covered

13 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	92.9%	13 ratings
Hold	7.1%	1 ratings
Sell	0.0%	0 ratings

Out of 14 total stock ratings issued by Andrew S. Fein at HC Wainwright, the majority (92.9%) have been Buy recommendations, followed by 7.1% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	13 companies

Andrew S. Fein, an analyst at HC Wainwright, currently covers 13 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 13 companies	100.0%

Andrew S. Fein of HC Wainwright specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 11 companies	84.6%
MED - DRUGS 2 companies	15.4%

About Andrew S. Fein

Mr. Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research. Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart. Mr. Fein has received numerous honorable mentions from the Institutional Investor All-America Research poll. Mr. Fein’s educational background includes a Bachelor of Arts degree from Yale University.

Follow on LinkedIn

Andrew S. Fein's Ratings History at HC Wainwright

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
TERN Terns Pharmaceuticals	9/4/2025	Initiated Coverage	$7.44	$7.44	Neutral	$0.00 00.00% ROI
MTVA MetaVia	9/4/2025	Initiated Coverage	$0.67	$12.00	Buy	$0.00 00.00% ROI
MDGL Madrigal Pharmaceuticals	9/4/2025	Initiated Coverage	$435.27	$500.00	Buy	$0.00 00.00% ROI
ARCT Arcturus Therapeutics	9/4/2025	Initiated Coverage	$17.19	$60.00	Buy	$0.00 00.00% ROI
AKRO Akero Therapeutics	9/4/2025	Initiated Coverage	$45.62	$72.00	Buy	$0.00 00.00% ROI
ETNB 89BIO	9/4/2025	Initiated Coverage	$9.24	$32.00	Buy	$0.00 00.00% ROI
SVRA Savara	9/3/2025	Boost Price Target	$3.39	$8.00	Buy	$0.00 00.00% ROI
WVE WAVE Life Sciences	9/3/2025	Reiterated Rating	$7.55	$22.00	Buy	$0.00 00.00% ROI
PVLA Palvella Therapeutics	8/15/2025	Boost Price Target	$46.10	$75.00	Buy	$0.00 00.00% ROI
SVRA Savara	8/15/2025	Upgrade	$3.01	$5.00	Buy	$0.00 00.00% ROI
ARVN Arvinas	8/7/2025	Lower Price Target	$6.11	$18.00	Buy	$0.00 00.00% ROI
DAWN Day One Biopharmaceuticals	8/6/2025	Lower Price Target	$6.88	$25.00	Buy	$0.00 00.00% ROI
VRTX Vertex Pharmaceuticals	8/5/2025	Lower Price Target	$472.27	$478.00	Buy	$0.00 00.00% ROI
PRTA Prothena	8/5/2025	Reiterated Rating	$6.94	$14.00	Buy	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.